BridgeBio Pharma (BBIO) Accumulated Expenses (2018 - 2026)

BridgeBio Pharma's Accumulated Expenses history runs 9 years deep, the most recent figure standing at $39.3 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 17.61% year-over-year to $39.3 million; the TTM figure through Mar 2026 stood at $39.3 million (up 17.61% YoY), while the FY2025 annual figure was $76.7 million, up 31.5% from the prior year.
• Accumulated Expenses came in at $39.3 million for Q1 2026 at BridgeBio Pharma, down from $76.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $76.7 million in Q4 2025 to a low of $300000.0 in Q2 2024.
• A 5-year average of $31.3 million and a median of $32.4 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses tumbled 98.29% in 2024 and jumped 4703.67% in 2025, its largest moves.
• BridgeBio Pharma's Accumulated Expenses stood at $17.5 million in 2022, then climbed by 1.49% to $17.8 million in 2023, then surged by 228.41% to $58.3 million in 2024, then soared by 31.5% to $76.7 million in 2025, then tumbled by 48.71% to $39.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $39.3 million, $76.7 million, and $56.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison